The Use of Papillomavirus Virus-Like Particles (VLPs) and Derivatives (including Capsomeres) as Microbicides


The present invention makes use of Papillomavirus VLPs as microbicidal agents to prevent or inhibit infection by papillomavirus or other viruses that utilize a shared papillomavirus binding receptor on the surface of cells and tissues. The composition of the microbicide contains a papillomavirus virus-like particle or capsomere that is sufficient to cause receptor blockade, and thereby prevent infection, yet is antigenically distinct from those papillomavirus genotypes that are components of current vaccines and, as such, are unlikely to induce tolerance against the components of those vaccines. Thus, the compositions and methods of the present invention can be used in combination with existing vaccines to prevent the spread of papillomavirus infections.



In addition to the knowledge of the prevalence of successful sexually transmitted disease (STD) and prevention strategies such as the use of condoms, monogamy, and abstinence, microbicides offer an alternate and feasible method for primary prevention of STDs. While there is great focus on the development of microbicides for the prevention of HIV transmission, little attention has been paid to their possible use for other STDs.


Novelty & Usefulness:

There are currently no microbiocides that have been shown to be effective

against papillomaviruses in clinical trials. The proposed approach would be effective against all genotypes of the virus.


Commercial Partners:

GlaxoSmithkline, Merck, Butanton Institute-Sao Paulo, Brazil


URV Reference Number: 6-1730
Patent Information:
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
William Bonnez